Skip to main content

Advertisement

Log in

Rasburicase treatment in severe tophaceous gout: a novel therapeutic option

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Hanan Abdel Rehim

References

  1. Fam AG (1999) Hyperuricemia and gout. In: Rakel RE (ed) Conn's current therapy, 51st edn. Saunders, Philadelphia, pp 561–566

    Google Scholar 

  2. Emmerson BT (1996) The management of gout. N Engl J Med 334:445–451

    Article  PubMed  CAS  Google Scholar 

  3. Terkeltaub RA (2003) Gout. N Engl J Med 349(17):1647–1655

    Article  PubMed  CAS  Google Scholar 

  4. Bieber JD, Terkeltaub RA (2004) Gout; on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50(8):2400–2414

    Article  PubMed  Google Scholar 

  5. Perez-Ruiz F, Alonzo-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545–549

    Article  PubMed  CAS  Google Scholar 

  6. Jansen TLThA, Reinders MK, Van Roon EN, Brouwers JRBJ (2004) Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 22(5):651

    PubMed  Google Scholar 

  7. Tausche AK, Richter K, Grässler A, Hänsel S, Roch B, Schröder HE (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351–1352

    Article  PubMed  CAS  Google Scholar 

  8. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093–1103

    Article  PubMed  CAS  Google Scholar 

  9. Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–555

    Article  PubMed  CAS  Google Scholar 

  10. Rozenberg S, Roch B, Dorent R, Koeger AC, Borget Wrona N, Bourgeois P (1995) Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum (Engl Ed) 62(5):392–394

    PubMed  CAS  Google Scholar 

  11. Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189–192

    Article  PubMed  CAS  Google Scholar 

  12. Seegmiller JE (1965) The acute attack of gouty arthritis. Arthritis Rheum 8:714–723

    Article  PubMed  CAS  Google Scholar 

  13. Li-Yu J, Clayburne G, Sieck M et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577–580

    PubMed  CAS  Google Scholar 

  14. Mc Carty DJ (1994) Gout without hyperuricemia. JAMA 271:302–303

    Article  PubMed  CAS  Google Scholar 

  15. Ferraz MB, O'Brien B (1995) A cost effective analysis of urate lowering drugs in non-tophaceous recurrent gouty arthritis. J Rheumatol 22:908–914

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. D. Moolenburgh.

Additional information

The presented case has been published before in a local Dutch mailing for rheumatologists.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moolenburgh, J.D., Reinders, M.K. & Jansen, T.L.T.A. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 25, 749–752 (2006). https://doi.org/10.1007/s10067-005-0043-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-005-0043-y

Keywords

Navigation